1. Seol W. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
BMB Rep 2010;43:233-244.
2. Gasser T. Update on the genetics of Parkinson's disease.
Mov Disord 2007;22 Suppl 17:S343-S350.
3. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention.
Lancet Neurol 2016;15:1257-1272.
4. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL. Risk and protective factors for Parkinson's disease: a study in Swedish twins.
Ann Neurol 2005;57:27-33.
5. Fuxe K, Ungerstedt U. Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists.
Med Biol 1974;52:48-54.
6. Hong CT, Chan L, Bai CH. The effect of caffeine on the risk and progression of Parkinson's disease: a meta-analysis.
Nutrients 2020;12:1860.
7. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease.
Mov Disord 2007;22:2242-2248.
8. Socala K, Szopa A, Serefko A, Poleszak E, Wlaz P. Neuroprotective effects of coffee bioactive compounds: a review.
Int J Mol Sci 2020;22:107.
9. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease.
Neurology 2003;60:790-795.
10. Xu K, Di Luca DG, Orru M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of parkinson's disease and its dependence on adenosine A2A receptors.
Neuroscience 2016;322:129-137.
11. Chen JF, Cunha RA. The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease.
Purinergic Signal 2020;16:167-174.
12. Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, et al. Caffeine as symptomatic treatment for Parkinson disease (Cafe-PD): a randomized trial.
Neurology 2017;89:1795-1803.
13. Miyazaki I, Isooka N, Wada K, Kikuoka R, Kitamura Y, Asanuma M. Effects of enteric environmental modification by coffee components on neurodegeneration in rotenone-treated mice.
Cells 2019;8:221.
14. Colombo R, Papetti A. An outlook on the role of decaffeinated coffee in neurodegenerative diseases.
Crit Rev Food Sci Nutr 2020;60:760-779.
15. Kim J, Lee S, Shim J, Kim HW, Kim J, Young JJ, et al. Caffeinated coffee, decaffeinated coffee, and the phenolic phytochemical chlorogenic acid up-regulate NQO1 expression and prevent H
2O
2-induced apoptosis in primary cortical neurons.
Neurochem Int 2012;60:466-474.
16. Lee M, McGeer EG, McGeer PL. Quercetin, not caffeine, is a major neuroprotective component in coffee.
Neurobiol Aging 2016;46:113-123.
17. Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, et al. Caffeine and risk of Parkinson's disease in a large cohort of men and women.
Mov Disord 2012;27:1276-1282.
18. Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease.
Exp Neurol 2017;298:210-224.
19. Bakshi R, Macklin EA, Hung AY, Hayes MT, Wills AM, et al. Associations of lower caffeine intake and plasma urate levels with idiopathic Parkinson's disease in the harvard biomarkers study.
J Parkinsons Dis 2020;10:505-510.
20. Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men.
Am J Epidemiol 2008;167:831-838.
21. Park KY, Kim HJ, Ahn HS, Park EJ, Yim SY, et al. Effects of coffee consumption on serum uric acid: systematic review and meta-analysis.
Semin Arthritis Rheum 2016;45:580-586.
22. Gigante AF, Asabella AN, Iliceto G, Martino T, Ferrari C, Defazio G, et al. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease.
Neurol Sci 2018;39:551-555.
23. Leite MR, Wilhelm EA, Jesse CR, Brandao R, Nogueira CW. Protective effect of caffeine and a selective A2A receptor antagonist on impairment of memory and oxidative stress of aged rats.
Exp Gerontol 2011;46:309-315.
24. Malar DS, Prasanth MI, Brimson JM, Sharika R, Sivamaruthi BS, Chaiyasut C, et al. Neuroprotective properties of green tea (Camellia sinensis) in Parkinson's disease: a review.
Molecules 2020;25:3926.
25. Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese health study.
Am J Epidemiol 2008;167:553-560.
26. Nefzger MD, Quadfasel FA, Karl VC. A retrospective study of smoking in Parkinson's disease.
Am J Epidemiol 1968;88:149-158.
27. Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson's disease in two prospective studies.
Ann Neurol 2001;50:780-786.
28. Ma C, Liu Y, Neumann S, Gao X. Nicotine from cigarette smoking and diet and Parkinson disease: a review.
Transl Neurodegener 2017;6:18.
29. Mappin-Kasirer B, Pan H, Lewington S, Kizza J, Gray R, Clarke R, et al. Tobacco smoking and the risk of Parkinson disease: a 65-year follow-up of 30,000 male British doctors.
Neurology 2020;94:e2132-e2138.
30. O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality.
Am J Epidemiol 2009;169:678-682.
31. Searles Nielsen S, Gallagher LG, Lundin JI, Smith-Weller T, Franklin GM, Swanson PD, et al. Environmental tobacco smoke and Parkinson's disease.
Mov Disord 2012;27:293-296.
32. O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, et al. Smokeless tobacco use and the risk of Parkinson's disease mortality.
Mov Disord 2005;20:1383-1384.
33. Gatto NM, Deapen D, Bordelon Y, Marshall S, Bernstein L, Ritz B. Passive smoking and Parkinson's disease in California teachers.
Parkinsonism Relat Disord 2017;45:44-49.
34. Bono F, Mutti V, Devoto P, Bolognin S, Schwamborn JC, Missale C, et al. Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson's disease patients carrying the LRRK2 G2019S mutation.
Neurobiol Aging 2021;99:65-78.
35. Villafane G, Thiriez C, Audureau E, Straczek C, Kerschen P, CormierDequaire F, et al. High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study.
Eur J Neurol 2018;25:120-127.
36. Trinh K, Andrews L, Krause J, Hanak T, Lee D, Gelb M, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson's disease through an NRF2-dependent mechanism.
J Neurosci 2010;30:5525-5532.
37. McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, et al. Exploring gene-environment interactions in Parkinson's disease.
Hum Genet 2008;123:257-265.
38. Peng B, Yang Q, Joshi RB, Liu Y, Akbar M, Song BJ, et al. Role of alcohol drinking in alzheimer's disease, parkinson's disease, and amyotrophic lateral sclerosis.
Int J Mol Sci 2020;21:2316.
39. Kamal H, Tan GC, Ibrahim SF, Shaikh MF, Mohamed IN, Mohamed RMP, et al. Alcohol Use disorder, neurodegeneration, alzheimer's and Parkinson's disease: interplay between oxidative stress, neuroimmune response and excitotoxicity.
Front Cell Neurosci 2020;14:282.
40. Liu R, Guo X, Park Y, Wang J, Huang X, Hollenbeck A, et al. Alcohol consumption, types of alcohol, and parkinson's disease.
PLoS One 2013;8:e66452.
41. Kim IY, Yang TO, Heath AK, Simpson RF, Reeves GK, Green J, et al. Alcohol intake and Parkinson's disease risk in the million women study.
Mov Disord 2020;35:443-449.
42. Karkhanis AN, Rose JH, Huggins KN, Konstantopoulos JK, Jones SR. Chronic intermittent ethanol exposure reduces presynaptic dopamine neurotransmission in the mouse nucleus accumbens.
Drug Alcohol Depend 2015;150:24-30.
43. Vaglini F, Viaggi C, Piro V, Pardini C, Gerace C, Scarselli M, et al. Acetaldehyde and parkinsonism: role of CYP450 2E1.
Front Behav Neurosci 2013;7:71.
44. Cahill CM, Aleyadeh R, Gao J, Wang C, Rogers JT. Alpha-Synuclein in alcohol use disorder, connections with Parkinson's disease and potential therapeutic role of 5' untranslated region-directed small molecules.
Biomolecules 2020;10:1465.
45. Cho BH, Choi SM, Kim BC. Gender-dependent effect of coffee consumption on tremor severity in de novo Parkinson's disease.
BMC Neurol 2019;19:194.
46. Lee Y, Oh JS, Chung SJ, Chung SJ, Kim SJ, Nam CM, et al. Does smoking impact dopamine neuronal loss in de novo Parkinson disease?
Ann Neurol 2017;82:850-854.
47. Kim R, Yoo D, Jung YJ, Han KD, Lee JY. Smoking cessation, weight change, and risk of Parkinson’s disease: analysis of national cohort data.
J Clin Neurol 2020;16:455-460.
48. Kang JH, Im JH, Cho IS, Lee M. Effects of smoking on patients with Parkinson’s disease. J Korean Neurol Assoc 2000;18:394-401.
49. van der Mark M, Nijssen PC, Vlaanderen J, Huss A, Mulleners WM, Sas AMG, et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking.
PLoS One 2014;9:e95297.
50. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease.
Neurobiol Aging 2003;24:197-211.
51. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases.
Mov Disord 2012;27:716-719.
52. Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease.
Mov Disord 2014;29:976-979.
53. Fratiglioni L, Wang HX. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies.
Behav Brain Res 2000;113:117-120.